At a Glance
Casdin Capital operates as a distinctive investment firm that bridges traditional venture capital with public market investing, maintaining a focus on healthcare and life sciences companies across multiple stages of development. Founded in 2012 by Eli Casdin, the New York-based firm has built a reputation for its deep sector expertise and ability to support companies through both private and public market phases. The firm's approach centers on identifying transformative healthcare technologies and therapeutic platforms, often taking concentrated positions in companies developing breakthrough medical devices, digital health solutions, and biotechnology innovations. Casdin Capital's investment strategy extends beyond typical VC boundaries, as the firm maintains both private and public investment capabilities, allowing them to maintain positions in portfolio companies through IPOs and beyond. This dual approach has proven valuable in the healthcare sector, where companies often require extended capital support through lengthy regulatory approval processes. The firm's portfolio spans digital health platforms, medical device companies, and biotechnology ventures, with particular attention to companies addressing large addressable markets in healthcare. Casdin Capital's team brings significant healthcare industry experience, including backgrounds in medicine, biotechnology development, and healthcare investing. The firm's $2.5 billion in assets under management reflects its growth since inception and ability to attract institutional capital for healthcare-focused investing. Their investment range spans from early-stage venture rounds through growth capital and public market positions, providing flexibility to support companies at various inflection points. The firm's New York headquarters positions it within the broader East Coast healthcare and financial ecosystem, while maintaining connections to key biotech hubs. Casdin Capital's reputation rests on its specialized healthcare focus and cross-stage investment capability, differentiating it from generalist VC firms and pure-play public market healthcare investors.
“Public and private investing at the intersection of biology, technology, and data science.”
Casdin Capital is led by founder Eli Casdin, who brings extensive experience in healthcare investing and public market expertise to the firm's investment approach. The team includes professionals with backgrounds spanning medicine, biotechnology development, and healthcare investing, providing the technical expertise necessary to evaluate complex life sciences opportunities. The firm's investment professionals combine financial analysis capabilities with deep healthcare sector knowledge, enabling them to assess both the scientific merit and commercial potential of healthcare technologies. This specialized expertise allows Casdin Capital to participate in due diligence processes that require understanding of regulatory pathways, clinical development timelines, and healthcare market dynamics.
Since its 2012 founding, Casdin Capital has raised multiple funds to reach its current $2.5 billion in assets under management. The firm's fund progression reflects its growing reputation in healthcare investing and ability to attract institutional capital for its specialized investment approach. The evolution of Casdin's funds demonstrates the firm's expansion from its initial healthcare focus while maintaining its core expertise in life sciences and medical technology investments.
Casdin Capital primarily invests at the Pre-Seed, Seed, Series A, Series B+ stages. This means they focus on companies that are at the earliest idea or prototype phase.
Casdin Capital is headquartered in New York, NY. Many of their portfolio companies are also based in this region, though they invest across geographies.
Casdin Capital focuses on investments in Aerospace & Defense, Digital Health, Other, Consumer, Fintech. Their portfolio reflects deep expertise and networks within these sectors.
Casdin Capital's typical investment check size ranges from $. to $.. Actual amounts may vary based on the stage, sector, and specific opportunity.
Casdin Capital manages approximately $2.5B in assets under management (AUM) across their funds.
